Project description:Analysis of differential expression of cyclic RNA in CD133 cells between sepsis patients and normal individuals Analysis of differential expression of cyclic RNA in CD133 cells between sepsis patients and normal individuals
Project description:We use gene expression data to provide a three-faceted analysis on the links between molecular subclasses of glioblastima, epithelial-to mesenchymal transition (EMT) and CD133 cell surface protein. The contribution of this paper is three-folded: First, we used a newly identified signature for epithelial-to-mesenchymal transition in human mammary epithelial cells, and demonstrated that genes in this signature have significant overlap with genes differentially expressed in all known GBM subtypes. However, the overlap between the genes up-regulated in the mesenchymal subtype of GBM and in the EMT signature was more significant than other GBM subtypes. Second, we provided evidence that there is a negative correlation between the genetic signature of EMT and that of CD133 cell surface protein, a putative marker for neural stem cells. Third, we studied the correlation between GBM molecular subtypes and the genetic signature of CD133 cell surface protein. We demonstrated that the mesenchymal and neural subtypes of GBM have the strongest correlations with the CD133 genetic signature. While the mesenchymal subtype of GBM demonstrates similarity with the signatures of both EMT and CD133, it also demonstrates some differences with each of these signatures that is partly due to the fact that the signatures of EMT and CD133 are inversely related to each other. Taken together this data sheds light on role of the mesenchymal transition and neural stem cells, and their mutual interaction, in molecular subtypes of glioblastoma multiforme.
Project description:6 benign TURP samples taken directly from patients were subjected to collagen digestion overnight. Epithelial cells isolated were adhered to collagen for 15 minutes. Adherent cells were passed through a magnetic bead column and cells positive for CD133 antibody were double selected. RNA was extracted from CD133+ and CD133- cells from each patient and amplified using the RiboAmp HS RNA amplification system. CD133+ (Cy5) and CD133- (Cy5) cDNA was hybridised to 30K cDNA array (CRUK facility) using the Invitrogen post labelling system. In each case that RNA was co-hybridised to a human pooled universal reference cDNA (Cy3). Keywords: repeat sample
Project description:Epithelial cell cultures derived from benign and HRPC tissue biopsies were expanded in culture for 2-3 weeks. CD133+ and CD133- cells were isolated using the miltenyi magnetic bead system after adherence to collagen. CD133+ and CD133- RNA was isolated and amplified using the RiboAmp HS kit and expression profiling performed using the CRUK WGA gene set. Keywords: Tumour vs normal comparison
Project description:We cultured tumor cells from 22 GBM under medium conditions favoring the growth of neural stem cells. 11 out of 15 primary GBM contained a significant CD133+ subpopulation that comprised cells showing all hallmarks of neural stem cells. Cell lines derived from these CD133+ GBM showed a neurosphere-like, non-adherent growth pattern. In contrast, 4 out of 15 cell lines derived from primary GBM grew adherent in vitro and were driven by CD133- tumor cells that fulfilled stem cell criteria. In vivo, these GBM were characterized by a significantly lower proliferation index but similar GFAP staining as compared to CD133+ GBM. Gene arrays from 2x3 representative cells lines are given. Keywords: Cancer stem cell, CD133, glioblastoma
Project description:CD133 has been widely used for identification and isolation of cancer stem cells in tumors although its role as a marker for cancer stem cell is still controversial . We isolated the CD133+ and CD133- cells from SW620 human colon cancer cell line and compared their biological characteristics, such as tumorigenicity,drug sensitivity, etc. Our study revealed that CD133+ SW620 cells were more tumorigenic and resistant to anti-cancer drugs. Correspondingly, they displayed different gene expression profile. However, it was observed that CD133- cells and CD133+ cells could mutually convert, indicating that CD133 expression was under dynamic and reversible regulations which might impose significant infulence on cells behaviors. Thus, our data challenge the role of CD133 as a marker for cancer stem cell.
Project description:Interventions: Practice of Circular dance moves: Intervention: It will start with an experimental group and one control group.
Experimental Group: (Sample Number 90 individuals); Intervention period: 12( twelve) weeks; frequency: 02 (twice) a week; duration: 60 (sixty minutes); Location: Reference Center in Integrative Practices (CERPIS) located at Planaltina, Federal District. Also, the potential individuals to undergo the intervention shall fulfill a questionaire for assessing quality of life perception, sociodemographic profiling, clinical evaluation and an interview.
Control Group: (Sample Number 90 individuals) The potential individuals whom shall undergo the intervention shall take part on avery aspect of the intervention except for the circular dance moves; Location: Reference Center in Integrative Practices (CERPIS) located at Planaltina, Federal District. Also, the potential individuals to undergo the intervention shall fulfill a questionaire for assessing quality of life perception, sociodemographic profiling, clinical evaluation as well as laboratory assays and an interview.;Other;E02.190.888.374;I03.450.642.287
Primary outcome(s): The primary outcome measure being considered is the intervention of the practice of dance move that will have a period of 12 intervention (twelve) weeks.
Shall be considererd, quantitative changes in the spectrum of the evaluation of perception of quality of life questionnaire (COH-QOL-OQ - City of Hope - Quality of Life Ostomy Questionnaire)), requiring a change of, at least, 5% in the values obtained prior to the intervention as well as when compared to the control group.
Study Design: Randomized controlled trial, parallel open, with two arms, cross.